Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
2.440
+0.030 (1.24%)
At close: Oct 22, 2026, 4:00 PM EDT
2.440
0.00 (0.00%)
After-hours: Oct 22, 2026, 4:25 PM EDT
Adagene Revenue
Adagene had revenue of $1.62M in the half year ending June 30, 2026. This brings the company's total for the last twelve months to $9.29M, up 8,902.38% year-over-year. In the year 2025, Adagene had annual revenue of $7.67M with 7,332.76% growth. That makes Adagene the 37,664th largest company in the world by revenue and 4,951st in the United States.
Revenue (ttm)
$9.29M
Revenue Growth
+8,902.38%
P/S Ratio
17.63
Revenue / Employee
$72,584
Employees
128
Market Cap
163.83M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.67M | 7.57M | 7,332.76% |
| Dec 31, 2024 | 103.20K | -18.01M | -99.43% |
| Dec 31, 2023 | 18.11M | 8.82M | 94.90% |
| Dec 31, 2022 | 9.29M | -882.53K | -8.67% |
| Dec 31, 2021 | 10.18M | 9.47M | 1,351.71% |
| Dec 31, 2020 | 700.91K | 220.91K | 46.02% |
| Dec 31, 2019 | 480.00K | -1.03M | -68.24% |
| Dec 31, 2018 | 1.51M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Coherus Oncology | 50.94M |
| Precision BioSciences | 45.06M |
| MediWound | 11.86M |
| Whitehawk Therapeutics | 7.15M |
| Entrada Therapeutics | 4.69M |
| Upstream Bio | 3.16M |
| Oramed Pharmaceuticals | 2.00M |
ADAG News
- 2 days ago - Adagene Transcript: Chardan's 10th Annual Healthcare Conference - Transcripts
- 7 days ago - Adagene Transcript: H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference - Transcripts
- 8 days ago - Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference - GlobeNewsWire
- 4 weeks ago - Adagene announces China’s NMPA approved IND for ADG138 - TheFly
- 4 weeks ago - Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager - GlobeNewsWire
- 5 weeks ago - Adagene Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 5 weeks ago - Adagene Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 6 weeks ago - Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology - GlobeNewsWire